Drug Details

General Information of the Drug (ID: DR4854)
Name
Roscovitine
Synonyms
Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H26N6O
PubChem CID
160355
Canonical SMILES
CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3
InChI
1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
InChIKey
BTIHMVBBUGXLCJ-OAHLLOKOSA-N
CAS Number
CAS 186692-46-6
GDSC
Roscovitine
TTD Drug ID
D05ADP
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Resveratrol      Gnetum parvifolium     Click to Show/Hide the Molecular Data of This NP
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Target and Pathway
Target(s) Cyclin-dependent kinase 1 (CDK1)  Molecule Info  [3]
Cyclin-dependent kinase 2 (CDK2)  Molecule Info  [3]
Cyclin-dependent kinase 7 (CDK7)  Molecule Info  [3]
KEGG Pathway Cell cycle Click to Show/Hide
2 Oocyte meiosis
3 p53 signaling pathway
4 Gap junction
5 Progesterone-mediated oocyte maturation
6 Herpes simplex infection
7 Epstein-Barr virus infection
8 Viral carcinogenesis
9 FoxO signaling pathway
10 PI3K-Akt signaling pathway
11 Hepatitis B
12 Measles
13 Pathways in cancer
14 Prostate cancer
15 Small cell lung cancer
16 Basal transcription factors
17 Nucleotide excision repair
NetPath Pathway RANKL Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Panther Pathway p53 pathway Click to Show/Hide
2 p53 pathway feedback loops 2
Pathway Interaction Database p73 transcription factor network Click to Show/Hide
2 E2F transcription factor network
3 PLK1 signaling events
4 AP-1 transcription factor network
5 FOXM1 transcription factor network
6 Retinoic acid receptors-mediated signaling
7 Regulation of nuclear SMAD2/3 signaling
8 Signaling events mediated by PRL
9 ATR signaling pathway
10 mTOR signaling pathway
11 IL2-mediated signaling events
12 FoxO family signaling
13 BARD1 signaling events
14 p53 pathway
15 Regulation of retinoblastoma protein
Reactome MAPK3 (ERK1) activation Click to Show/Hide
2 E2F mediated regulation of DNA replication
3 G0 and Early G1
4 Cyclin B2 mediated events
5 Golgi Cisternae Pericentriolar Stack Reorganization
6 Cdc20:Phospho-APC/C mediated degradation of Cyclin A
7 Regulation of APC/C activators between G1/S and early anaphase
8 Phosphorylation of the APC/C
9 Phosphorylation of Emi1
10 Condensation of Prophase Chromosomes
11 MASTL Facilitates Mitotic Progression
12 Resolution of Sister Chromatid Cohesion
13 Condensation of Prometaphase Chromosomes
14 Regulation of PLK1 Activity at G2/M Transition
15 Activation of NIMA Kinases NEK9, NEK6, NEK7
16 Loss of Nlp from mitotic centrosomes
17 Recruitment of mitotic centrosome proteins and complexes
18 Loss of proteins required for interphase microtubule organization?from the centrosome
19 Recruitment of NuMA to mitotic centrosomes
20 Depolymerisation of the Nuclear Lamina
21 Anchoring of the basal body to the plasma membrane
22 MAPK6/MAPK4 signaling
23 G1/S-Specific Transcription
24 Cyclin A/B1 associated events during G2/M transition
25 G2/M DNA replication checkpoint
26 Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
27 Activation of ATR in response to replication stress
28 SCF(Skp2)-mediated degradation of p27/p21
29 Senescence-Associated Secretory Phenotype (SASP)
30 DNA Damage/Telomere Stress Induced Senescence
31 Processing of DNA double-strand break ends
32 G2 Phase
33 Orc1 removal from chromatin
34 Cyclin E associated events during G1/S transition
35 p53-Dependent G1 DNA Damage Response
36 Cyclin A:Cdk2-associated events at S phase entry
37 Meiotic recombination
38 Factors involved in megakaryocyte development and platelet production
39 NoRC negatively regulates rRNA expression
40 Formation of TC-NER Pre-Incision Complex
41 Dual incision in TC-NER
42 Gap-filling DNA repair synthesis and ligation in TC-NER
43 Cyclin D associated events in G1
44 RNA Polymerase I Transcription Initiation
WikiPathways DNA Damage Response Click to Show/Hide
2 G1 to S cell cycle control
3 TGF beta Signaling Pathway
4 PPAR Alpha Pathway
5 MAP kinase activation in TLR cascade
6 RAF/MAP kinase cascade
7 Mitotic Prophase
8 Mitotic Prometaphase
9 BMI1
10 ATM Signaling Pathway
11 Retinoblastoma (RB) in Cancer
12 Spinal Cord Injury
13 Prostate Cancer
14 Regulation of Microtubule Cytoskeleton
15 Integrated Cancer pathway
16 Mitotic G2-G2/M phases
17 Mitotic G1-G1/S phases
18 Cell Cycle
19 APC/C-mediated degradation of cell cycle proteins
20 Cell Cycle Checkpoints
21 miRNA Regulation of DNA Damage Response
22 ID signaling pathway
23 DNA Replication
24 M/G1 Transition
25 S Phase
26 Meiotic Recombination
27 Aryl Hydrocarbon Receptor
28 Integrated Pancreatic Cancer Pathway
29 Oncostatin M Signaling Pathway
30 Signaling Pathways in Glioblastoma
31 TSH signaling pathway
32 Integrated Breast Cancer Pathway
33 Synthesis of DNA
34 Regulation of DNA replication
35 Factors involved in megakaryocyte development and platelet production
36 Eukaryotic Transcription Initiation
37 Cardiac Hypertrophic Response
38 HIV Life Cycle
39 Nucleotide Excision Repair
40 RNA Polymerase II Transcription
41 RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
42 mRNA Capping
43 MicroRNAs in cardiomyocyte hypertrophy
References
Reference 1 ClinicalTrials.gov (NCT02160730) Treatment of Cushing's Disease With R-roscovitine. U.S. National Institutes of Health.
Reference 2 Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem Toxicol. 2008 Apr;46(4):1327-33.
Reference 3 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
 Download Picture         KEGG Link